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Abstract
Background: Extramammary Paget's disease is a cutaneous neoplasm that
presents as erythematous crusted patches and plaques reminiscent of contact
dermatitis or inverse psoriasis that can be a challenge to treat in a tissue-sparing
manner. The most commonly involved site for this rare disorder is the anogenital
region. Surgery is considered as the gold standard therapy. In the last years, the
topical use of imiquimod cream in the treatment of this condition has been reported.
Main observations: We present a case of a 59-year-old woman with primary
extramammary Paget’s disease of the vulva, in which a conservative approach
to therapy was desired, and who underwent complete and stable remission with
imiquimod cream. We also review the previous reports of patients with
extramammary Paget's disease treated with imiquimod cream.
Conclusions: Imiquimod therapy may be an alternative for primary as well as
recurring extramammary Paget's disease. Treatment-associated morbidity is
minimal compared with other therapies, such as surgery which may be debilitating.
(J Dermatol Case Rep. 2011; 5(3): 42-46)
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Introduction
Extramammary Paget’s disease (EMPD) is an uncommon
intraepithelial adenocarcinoma, which occurs most com-
monly in the anogenital region, but can also arise in any area
of skin or mucosa.1 It is thought to originate from intraepi-
dermal apocrine glands or from pluripotent keratinocyte
stem cells. This disease occurs most frequently in postme-
nopausal women and on the vulva. Because of its multifo-
cal nature with indistinct demarcation and the resulting high
recurrence rate, EMPD is difficult to treat, and radical sur-
gery with large margins is often considered. The well-known
association of EMPD with underlying malignancy contribu-
tes also to the therapeutic challenge.2
Current recommended treatments for EMPD are surgical
excision, preferably Mohs' micrographic surgery, laser abla-
tion, electrodessication and curettage, photodynamic the-
rapy, radiotherapy as well as topical use of 5-fluorouracil.3
Topical application of imiquimod 5% cream has been repor-
ted in the last years with successful results.3-14 We report
the case of a woman with primary vulvar Paget’s disease,
who underwent successful treatment with imiquimod cre-
am, and review the published cases with EMPD treated to
date with this therapy.
Case report
A 59-year-old female patient consulted for a fluctuating so-
re and itchy zone in her vulva, present since several months.
Physical examination revealed a poorly delimited erythema-
to-squamous patch on the right labia major, with a diame-
ter of 1-2 cm (Fig. 1A). The lesion was preliminary diagno-
sed as genital seborrhoic dermatitis and probatorily treated
with a cream containing lithium succinate and zinc sulfate.
As the lesion didn't improve, and aeras of superficial mace-
ration and erosion developed a larger differential diagnosis
was considered, including contact dermatitis, psoriasis in-
versa, Bowen’s disease and EMPD.
A skin biopsy revealed the presence of large cells with abun-
dant pale cytoplasm and pleomorphic nuclei in all layers of
the epidermis (Fig. 2), spreading in the epithelium of the follicular
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As the patient also privileged a non-invasive therapy if po-
ssible, a treatment with imiquimod 5% cream in first inten-
tion was initiated. Imiquimod 5% cream was applied to the
vulvar lesion, including a 1-2 cm circumferential margin of
normal-appearing skin, before bedtime three times a week,
for 18 weeks.
Under therapy the patient developed moderate to at mo-
ment intense inflammation of the site of imiquimod appli-
cation, but without other side effects. Clinical controls at 1,
3, 6 months and one year after the end of therapy revealed
complete healing and normal skin without clinical signs of
recurrence of EMPD (Fig. 1B). Blood parameters, gynaeco-
logical and urological examinations, thorax-radiography, ul-
trasonography of the abdomen, basin and lymph nodes we-
re all normal at 1 year after therapy, confirming the comple-
te remission. A follow-up screening with yearly gynaecolo-
gical and urological examinations was recommended to the
patient.
structures, without invasion of the dermis. Immunohisto-
chemical staining was positive for total keratins and cytoke-
ratin 7 (Fig. 3), while staining for S100 was negative. A dia-
gnosis of vulvar Paget’s disease was made. The patient was
addressed to our clinic for management and therapy.
Upon further examination, total body skin and lymph nodes
palpation examination was normal. A tumour screening in-
cluding a computer tomography of the thorax and abdomen,
blood inflammatory parameters, the tumour marker CA-125,
as well as an ileocoloscopy, a gynaecological and a urologi-
cal examination with urine cytology revealed no pathology.
Because of the good prognosis of EMPD at this location
in the absence of underlying or associated disease in a rela-
tively young patient, we were reluctant to choose a surgical
therapy in first intention. Given the age of the patient, radio-
therapy, associated to possible late side effects, was also
considered as second- or third-line. Furthermore, the lesion
was deep as assessed by histology for an approach with pho-
todynamic therapy.
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Figure 1
1A. Lesion at diagnosis, before Imiquimod therapy.
1B. Lesion 3 months after the end of Imiquimod therapy.
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Figure 2
HE staining: large atypical cells with abundant cytoplasm in
the epidermis.
Figure 3
Immunohistochemical staining with cytokeratin 7.
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Table 1. Case reports/series of extramammary Paget disease treated by imiquimod.
Author (year)
Nr of
cases
Age Disease Dosage
Treatment
duration
(weeks)
Follow-up
(months) Outcome
Adverse
events
Zampogna (2002)15 2
54
72
scrotum,
recurrent
perineal,
primer
16
7.5
12
4
CR
CR
flu-like
symptoms;
nausea,
vomiting
Berman (2003)14 1 68 scrotum,
recurrent
1x/d 6 6 CR, HR
local
erythema
Qian (2003)12 1 73 penile shaft 3x/week 6 14 CR, HR minimal
Wang (2003)11 1 75
vulva,
recurrent
1x/d: 6d,
2x/week: 1w,
3x/week: 5w
7 0.5 CR, HR localirritation
Cohen (2006)3 1 75 suprapubic,
primer
3x/week 16 9 CR, HR local
erythema
Vereecken (2007)10 1 66 perianal,
recurrent
1x/day 12 12 CR, HR -
Geisler (2008)9 1 80 vulva,
reccurent
- - 12 CR, HR -
Hatch (2008)8 2
68
60
vulva,
reccurent
vulva,
reccurent
every other day,
1x/d: 4w;
2x/day: 2w,
every day:5w
24
20
4
7
CR, HR
CR, HR
pain,
erosion;
pain,
ulceration
1x/d: 6d, every
other day: 15w;
every other day:
7.5w
CR: complete clinical remission; PR: partial clinical remission; HR: histological remission; d: day; w: week
Challenor (2009)7 2
48
66
surgical not
in toto
surgical not
in toto
3x/week
3x/week
12
12
4
3
follow-up
follow-up
-
Bertozzi (2009)6 1 71 vulva,
reccurent
- 8 - CR local itching
Sendagorta (2010)5 3
66
58
82
vulva, primer
vulva, primer
vulva, primer
both: 1x/d: 3w,
every other
day: 3w
6
6
6
26
22
20
CR, HR
CR, HR
CR, HR
-
local
irritation
-
Tonguc (2010)4 1 65 vulva,
reccurent
every day: 3w;
1w break; every
other day: 14w
18 24 CR erosion
Summary of
reported cases
Total:
17
mean: 11.4
median: 10
range: 6-24
mean: 11.2
median: 10.5
range: 0.5-26
at least 3 times each week for a minimum of 8 weeks, and
as long as 16 weeks3, whereas Sendagorta et al. recommen-
ded daily application for 3 weeks, followed by an every other
day application for another 3 weeks.5 Long-term follow-up
of these patients is mandatory.
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Discussion
Local surgical excision with a 1 cm margin of normal skin
is the standard treatment option for EMPD.2 Since recurren-
ce rates between 16-50% are seen after regular surgery,15
Mohs micrographic surgery has become the preferred tre-
atment modality for EMPD.16 Despite this, recurrences ra-
tes of 27% following Mohs surgery have been reported.17
Other treatment options are laser ablation, electrodessica-
tion and curettage, photodynamic therapy, radiotherapy as
well as topical use of bleomycine and 5-fluorouracil.3 Re-
cently, immunotherapy with topical imiquimod 5% cream
has been successfully used to treat isolated cases of EMPD.
Table 1 summarizes the reported cases to date. According
to published reports and our experience, use of imiquimod
in the treatment of EMPD is safe and effective. Treatment of
primary or recurrent EMPD with imiquimod has been repor-
ted in a total of 17 patients, with a complete response re-
ported in 15. The total treatment duration varied from 6 to
24 weeks with a regimen usually starting as a daily applica-
tion and then tapering of the treatment to one application
every other day. The longest follow-up period reported in
the literature is 26 months (1 case).
Imiquimod is a topically applied imidazoquinoline immu-
nomodulator that binds to the toll-like receptor 7 and local-
ly induces the production of proinflammatory chemokines
and cytokines. Its use has been approved in the treatment
of human papilloma virus warts.
On average, 25% of cases of EMPD are associated with an
underlying cutaneous adnexal adenocarcinoma and show a
higher mortality rate (46%) than that of patients with EMPD
without underlying cutaneous adnexal adenocarcinoma.18
The location of the underlying internal malignancy is gene-
rally closely related to the location of the EMPD. A directed
search for internal malignancy is therefore mandatory in pa-
tients who are diagnosed with EMPD18 including a comple-
te skin examination, palpation of lymph nodes, rectal exa-
mination, colonoscopy, and cystoscopy, in addition a gyna-
ecological examination including pelvic and breast examina-
tion as well as colposcopy in women.19 Pelvic and abdomi-
nal ultrasonography have been also recommended.20
Conclusion
The advantages of imiquimod therapy are the minimal
morbidity associated with the treatment in comparison to
the currently alternative therapies available, as well as the
self-application by the patient. In our opininion, imiquimod
should be used exclusively in cases of EMPD limited to the
skin (primary cutaneous form). Our case and the review of
other cases reported to date underline the potential of imi-
quimod as first-line treatment of primary cutaneous EMPD.
Larger controlled trials are needed before this option can be
accepted as a standard first-line therapy for primary cutane-
ous EMPD. Furthermore, the frequency of application and
total duration of therapy should be harmonized and valida-
ted. Cohen et al. recommend topical therapy with imiquimod
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